Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Leach

Showing results (81-90 of 127) with videos related to

Pageof 13
Sort By:
The Journal of Experimental Medicine|July 1, 1996
T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient miceN J Davidson, M W Leach, M M Fort, et al.
Toxicologic Pathology|June 5, 1999
Renal changes associated with naproxen sodium administration in cynomolgus monkeysM W Leach, D W Frank, M R Berardi, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 10, 2013
Eliciting and Combining Decision Criteria Using a Limited Palette of Utility Functions and Uncertainty Distributions: Illustrated by Application to Pest Risk AnalysisJohnson Holt, Adrian W Leach, Gritta Schrader, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytesShu-Cheng Chen, Michael W Leach, Yuetian Chen, et al.
Regulatory Toxicology and Pharmacology : RTP|March 26, 2018
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumabMarjorie A Peraza, Karen E Rule, Michael H I Shiue, et al.
Toxicology and Applied Pharmacology|February 12, 2024
Translation of nonclinical to clinical safety findings for 27 biotherapeuticsMichael W Leach, Payal Rana, Wenyue Hu, et al.
American Journal of Clinical Oncology|May 8, 2012
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonatesVivek Thumbigere-Math, Lam Tu, Sabrina Huckabay, et al.
Regulatory Toxicology and Pharmacology : RTP|February 2, 2020
Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumabMazin Derzi, Ahmed M Shoieb, Sharon L Ripp, et al.
Journal of Translational Medicine|April 28, 2010
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeysYulia Vugmeyster, Scott Allen, Pamela Szklut, et al.
Toxicologic Pathology|February 28, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. BiotherapeuticsKendall S Frazier, Jeffery A Engelhardt, Pierluigi Fant, et al.
Pageof 13

Showing results (81-90 of 127) with videos related to

Sort By:
Pageof 13
The Journal of Experimental Medicine|July 1, 1996
T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient miceN J Davidson, M W Leach, M M Fort, et al.
Toxicologic Pathology|June 5, 1999
Renal changes associated with naproxen sodium administration in cynomolgus monkeysM W Leach, D W Frank, M R Berardi, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis|July 10, 2013
Eliciting and Combining Decision Criteria Using a Limited Palette of Utility Functions and Uncertainty Distributions: Illustrated by Application to Pest Risk AnalysisJohnson Holt, Adrian W Leach, Gritta Schrader, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 22, 2002
Central nervous system inflammation and neurological disease in transgenic mice expressing the CC chemokine CCL21 in oligodendrocytesShu-Cheng Chen, Michael W Leach, Yuetian Chen, et al.
Regulatory Toxicology and Pharmacology : RTP|March 26, 2018
Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumabMarjorie A Peraza, Karen E Rule, Michael H I Shiue, et al.
Toxicology and Applied Pharmacology|February 12, 2024
Translation of nonclinical to clinical safety findings for 27 biotherapeuticsMichael W Leach, Payal Rana, Wenyue Hu, et al.
American Journal of Clinical Oncology|May 8, 2012
A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonatesVivek Thumbigere-Math, Lam Tu, Sabrina Huckabay, et al.
Regulatory Toxicology and Pharmacology : RTP|February 2, 2020
Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumabMazin Derzi, Ahmed M Shoieb, Sharon L Ripp, et al.
Journal of Translational Medicine|April 28, 2010
Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeysYulia Vugmeyster, Scott Allen, Pamela Szklut, et al.
Toxicologic Pathology|February 28, 2015
Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. BiotherapeuticsKendall S Frazier, Jeffery A Engelhardt, Pierluigi Fant, et al.
Pageof 13